Statin drug trial halted six months early after success
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.One of the largest trials of a cholesterol-lowering drug ever conducted was halted more than six months early after dramatic reductions in illness and death were seen in treated patients.
The Jupiter trial investigated the effects of rosuvastatin on almost 18,000 patients with low to normal cholesterol levels but raised concentrations of an inflammation protein, C-reactive protein (CRP).
Under normal circumstances, the patients would not be considered at risk of suffering a heart attack, stroke, or dying from a heart-related cause. Yet those receiving medium doses of the drug, sold as Crestor, experienced far fewer adverse heart events than those given a placebo.
Heart attack risk was reduced by 54 per cent and stroke by 48 per cent. The combined risk of heart attack, stroke and heart-related death fell by 47 per cent, as did the odds of undergoing surgical procedures. Because the benefits were so clear, an independent monitoring board halted the trial early last March.
Hazard reductions were similar for men and women, and groups normally assumed to be at very low risk were found to benefit.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments